As Avricore Health Inc. prepares to release its earnings on May 29, investors are eager to see how the company's HealthTab™ expansion affects its financials. With a market cap of just CA$5.57M and a forward P/E of 0x, the stakes are high for this small-cap player.
Avricore Health Inc. (AVCR.V) is set to report its earnings for the fiscal period ending March 31, 2026, before the market opens on May 29. While no EPS estimates have been provided, the company's recent initiatives in the UK, particularly the expansion of its HealthTab™ platform, could be pivotal in shaping investor sentiment.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Avricore Health Inc
AVCR.V
AVCR.V
Avricore Health Inc
WealthAwesomeMarket cap
$7.58M
52W high
$0.10
52W low
$0.04
1W change
+18.18%
Beta
0.32
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCR's historical volatility
30-Day Vol
131.9%
Annualized
90-Day Vol
110.3%
Annualized
Trend (90d)
-31.1%
Annualized drift
90d Mean
C$0.06
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.06 | C$0.04 – C$0.10 |
| 60 trading days | C$0.06 | C$0.03 – C$0.11 |
| 90 trading days | C$0.06 | C$0.03 – C$0.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Long-term investors should closely monitor Avricore's earnings report for insights into its growth trajectory and market positioning.
A Closer Look at Avricore's Financial Metrics Ahead of Earnings
With a forward P/E of 0x and a market cap of CA$5.57M, Avricore Health Inc. is in a challenging financial position. The absence of positive earnings per share highlights the hurdles it faces, making the upcoming earnings report crucial for assessing its viability in a competitive health tech landscape.
Bull case
- HealthTab™ Growth: The ongoing expansion of the HealthTab™ platform into community pharmacies in North East London could boost revenue and strengthen market presence.
- Positive Industry Trends: The growing focus on health technology in the UK may create a supportive environment for Avricore's innovations.
- Recognition: Being listed in Deloitte's Technology Fast 50™ could enhance investor confidence and attract potential partnerships.
Bear case
- Financial Performance: With a TTM EPS of CA$-0.02 and a profit margin of 0.00%, concerns about profitability might affect investor sentiment.
- Market Cap Limitations: A small market cap of CA$5.57M could hinder the company's ability to scale operations effectively.
- Dependence on UK Expansion: The success of international initiatives like HealthTab™ is crucial; any setbacks could significantly impact financial results.
Avricore Health Inc. (AVCR.V)
Overview Avricore Health Inc. focuses on health technology, particularly its HealthTab™ platform, which aims to provide pharmacy-based blood test results. The company is expanding its services in the UK. What to Watch With no EPS estimates available, investors will be keen to see how the company's recent expansions and partnerships impact its financial performance. The last fiscal period ended March 31, 2026, will be critical for understanding its growth trajectory. Risks and Watch Items The company faces challenges with profitability, as indicated by its negative EPS and zero profit margin. Investors should also consider the risks associated with its international expansion efforts and market competition.
Advertisement
